WASHINGTON — A Department of Veterans Affairs committee has declined to approve widespread coverage of a new depression treatment that has generated controversy but also received an express endorsement from President Trump. Instead, the drug was approved on a more limited basis.
Many experts have embraced the medication, which is known as esketamine and is being sold by Johnson & Johnson (JNJ) under the brand name Spravato, as a critical option for patients in dire need of new treatments — particularly because it might work faster than existing antidepressants.
My neurologist offered esketamine infusion for my depression. I declined, although I knew it to be safe. Cannabidiol has been much better for my depression.
and then there’s the suspicious connection to the orange one’s Mar-a-Lago troika of VA ‘advisors’. More here: https://www.theguardian.com/us-news/2019/jun/17/spravato-ketamine-like-drug-that-experts-doubt-and-trump-is-pushing-on-veterans